23 / 34
Nivolumab +
Chemotherapy
Chemotherapy
•
TMB ≥10 mut/Mb: ORR was 60.5% with nivo + chemo and 20.8% with chemo
•
TMB <10 mut/Mb: ORR was 27.8% with nivo + chemo and 22.0% with chemo
43
36
21
14
9
5
2
0
No. at risk
48
30
16
4
1
1
1
0
Chemo
Nivo + chemo
(n = 43)
Chemo
(n = 48)
Median PFS,
a
mo
6.2
5.3
HR
(95% CI)
0.56
(0.35, 0.91)
Nivolumab +
chemotherapy
Months
Chemotherapy
0
20
40
60
80
100
0
6
12
18
3
9
15
21
TMB ≥10 mut/Mb and <1% Tumor PD-L1 Expression
1-y PFS = 27%
1-y PFS = 8%
Months
TMB <10 mut/Mb and <1% Tumor PD-L1 Expression
Nivo + chemo
(n = 54)
Chemo
(n = 59)
Median PFS,
b
mo
4.7
4.7
HR
(95% CI)
0.87
(0.57, 1.33)
0
20
40
60
80
100
0
6
12
18
3
9
15
21
1-y PFS = 18%
1-y PFS = 16%
54
38
19
13
6
3
0
0
59
39
16
6
6
3
1
0
Nivo + chemo
No. at risk
Chemo
PFS (%)
Nivo + chemo
Nivo + Chemo in 1L NSCLC
PD-L1 Negative & High TMB (>10 mut/MB)
H Borghaei et al.,. ASCO 2018